Navigation Links
MEI Pharma Acquires PWT143, A Highly Selective PI3-Kinase Delta Inhibitor
Date:9/10/2013

ry and pre-clinical development of PWT143 to date," said Julie Cherrington, Ph.D., President and Chief Executive Officer of Pathway Therapeutics. "We continue to believe strongly in its potential to be an important drug for patients, and we are pleased that it is going into the hands of a team with the resources and drug development expertise to maximize that potential."

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's lead drug candidate is Pracinostat, a potential best-in-class, oral HDAC inhibitor being developed for advanced hematologic diseases, such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Results from a pilot Phase II clinical trial of Pracinostat in combination with Vidaza (azacitidine) in patients with MDS presented at the American Society of Hematology Annual Meeting in December 2012 showed an overall response rate of 89% (eight out of nine). In June 2013, the Company initiated a randomized, placebo-controlled Phase II trial of Pracinostat in combination with Vidaza in patients with previously untreated MDS. An open-label Phase II trial of Pracinostat in combination with Vidaza in elderly patients with AML unsuitable for induction therapy is expected to initiate in the fall of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a first-in-human Phase I trial of ME-344 in patients with solid refractory tumors are anticipated in October 2013. For more information, go to www.meipharma.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe a
'/>"/>

SOURCE MEI Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
2. Roche and Inovio Pharmaceuticals partner on Inovios prostate cancer and hepatitis B immunotherapy products
3. UHC to Launch New Specialty Pharmacy Program for Better Continuity of Patient Care, Improved Access to Specialty Pharmaceuticals
4. Pharmaceutical Giants Back Researchers in Unique US Competition
5. Several Market Access Drivers Provide Attractive Opportunities for Multinational Companies in Saudi Arabias Pharmaceutical Market
6. DelMar Pharmaceuticals and Guangxi Wuzhou Pharmaceuticals Establish Clinical Advisory Board in China
7. Sunshine Act 2013 Updates: A Checklist for Pharmaceutical Companies to Meet CMS Reporting
8. PDL BioPharma Provides Third Quarter 2013 Revenue Guidance of $97 Million
9. Biogen Idec and Isis Pharmaceuticals Announce Strategic Collaboration to Advance Treatment of Neurological Disorders
10. Altaire Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of 9 lots of Carboxymethylcellulose Sodium 0.5% Ophthalmic Solution sold under several brands
11. SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of Astex Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... CHAPEL HILL, N.C. , March 27, 2015 /PRNewswire/ ... an intimidating job description: ensure products meet quality standards ... tight budgets and escalating regulations, quality leaders also have ... costs and risk. Those who don,t effectively ... quality function as well as marketplace failure and regulatory ...
(Date:3/27/2015)... March 27, 2015 /PRNewswire/ - Medicure Inc. (the "Company") ... has approved the grant of an aggregate of 236,070 ... and consultants of the Company pursuant to the Company,s ... to expire on the tenth anniversary of the date ... third anniversary of the date of grant and 50,000 ...
(Date:3/27/2015)... WASHINGTON , March 27, 2015 ... - The biopharmaceutical industry comes out on top as ... in a new report  from ndp│analytics. According to ... and development (R&D) investment over the last decade, accounting ... 2000-2012. A Short Video on ...
Breaking Medicine Technology:New Medical Device Quality Study Finds Regulatory Environment is Boosting Quality Spending, Especially for Large Companies 2Week in Review: The Latest from PhRMA 2
... 17 Regado Biosciences, a privately held company leading the ... David J. Mazzo , PhD, President and CEO, will be presenting ... in Boston, Massachusetts . Dr. Mazzo,s presentation will be given ... in the Robinson Room and will include an overview of ...
... June 17 Salvin Dental Specialties, Inc. and LifeNet Health ... advance LifeNet Health,s OraGraft™ allograft products in the dental market. , ... The two companies ... the existing relationship between these two companies, which provides LifeNet Health ...
Cached Medicine Technology:Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts 2Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts 3LifeNet Health and Salvin Dental Specialties Announce Partnership 2LifeNet Health and Salvin Dental Specialties Announce Partnership 3
(Date:3/29/2015)... (PRWEB) March 29, 2015 Youth Villages ... counties in Oregon to assess the feasibility of implementing ... emotional and behavioral problems and their families. , Third ... select participants that will be provided technical assistance throughout ... counties join six other national awardees chosen by Third ...
(Date:3/29/2015)... Chicago, IL (PRWEB) March 29, 2015 ... W. Brickner, “and as we learn more about the ... , In March Homeostasis: Publius’ Go Endo-Cannabinoid Update ... homeostatic health, or endo-healing, is celebrated. Publius, of The ... four 2015 National Institutes of Health (PubMed) cannabinoid system ...
(Date:3/28/2015)... AZ. (PRWEB) March 28, 2015 Could ... to a new study by researchers at ... , Produced with the support of the Coffee and ... journal Molecular Psychiatry this past fall, the study—one of ... meta-analysis of genomic data from more than 120,000 regular ...
(Date:3/28/2015)... With more than 4,500 scientists, clinicians and ... and musculoskeletal diseases gathered here for the World ... time in the 17-year history of the field’s ... is an emerging non-pharmaceutical protocol for enhancing bone ... Wolff’s law, osteogenic loading at multiples of body ...
(Date:3/28/2015)... York, NY (PRWEB) March 28, 2015 ... that offers urgent care in Manhattan, recently commemorated its ... care facility in Manhattan. In addition to 24-hour urgent ... ER facilities. , At this time, Emergency Medical ... for abdominal pain, asthma, chest pain, eye injuries, ear ...
Breaking Medicine News(10 mins):Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 2Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 4Health News:March Homeostasis: Publius’ Go Endo-Cannabinoid Update ~ New on the Bryan William Brickner Blog 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2
... memory in Alzheimer disease mice , Overactivation of ... formation, has been linked to Alzheimer disease. Ottavio Arancio ... shown that two different drugs that inhibit calpains can ... (APP/PS1 mice), leading them to suggest drugs that target ...
... Goals of All Parties -, MONETT, Mo., July ... ), a leading provider of integrated technology solutions,and data ... agency outsourcing solution has been bought by the,business line,s ... the,transaction were not disclosed., Banc Insurance Services, Inc. ...
... ABABA, Ethiopia, July 1 The U.S.,Agency for International ... the USA to combat HIV/AIDS in Ethiopia. The program ... vital medical,services and improve existing care and prevention programs ... and Adama. It will,also build community networks by means ...
... rise with temperatures , , TUESDAY, July 1 (HealthDay News) -- ... heat-related health issues because their bodies don,t cool down as ... not feel hot when the temperature is dangerously high and ... bodies have lost too much water," Dr. John B. Murphy, ...
... guide Foundation,s efforts, including polio,eradication, EVANSTON, Ill., July ... office on July 1 as chair of The,Rotary Foundation ... polio in its last remaining strongholds -- which include ... Foundation this year," said Majiyagbe.,"It is abundantly clear to ...
... SALT LAKE CITY, July 1 Dynatronics,Corporation (Nasdaq: ... a,letter from NASDAQ stating that for the last 30 ... has closed below the minimum $1.00 per,share requirement for ... company will be given 180 calendar days, or until ...
Cached Medicine News:Health News:JCI online early table of contents: July 1, 2008 2Health News:JCI online early table of contents: July 1, 2008 3Health News:JCI online early table of contents: July 1, 2008 4Health News:JCI online early table of contents: July 1, 2008 5Health News:JCI online early table of contents: July 1, 2008 6Health News:Jack Henry & Associates Divests Insurance Agency Outsourcing Business Line 2Health News:Jack Henry & Associates Divests Insurance Agency Outsourcing Business Line 3Health News:USAID Announces Youth-Focused HIV/AIDS Programs in Ethiopia 2Health News:Extreme Heat a Deadly Risk for Older Adults 2Health News:The Rotary Foundation's First African Trustee Chair Takes Office 2Health News:The Rotary Foundation's First African Trustee Chair Takes Office 3Health News:Dynatronics Receives NASDAQ Minimum Bid Price Deficiency Letter 2
VERSAPORT™ Plus RT Single Use Obturators for use with VERSAPORT™ RT Reusable Cannulae....
The Auto Suture™ Woodford Spike™ Trocar and Cannula is a sterile, single-use device designed for primary punctures during laparoscopy. Dexide refers to a separate offering of trocars from...
... complete line of Surgical Access ...unlike any ... OnePort™ trocar system is actually four systems ... operationally flexible and clinically adaptive to all ... in disposability and bladed or dilating tip ...
Thoracoscopy Cannula, reusable, hook electrode, two lengths, mini or basic kit....
Medicine Products: